{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+fluids",
    "query": {
      "intervention": "IV fluids"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 443,
    "total_pages": 45,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+fluids&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T06:32:50.747Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06823115",
      "title": "Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury",
        "Fluid Overload",
        "Prematurity Complications",
        "Risk Factors",
        "Epidemiology",
        "Chronic Kidney Disease(CKD)",
        "Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Minutes",
        "maximum_age": "2 Weeks",
        "sex": "ALL",
        "summary": "0 Minutes to 2 Weeks"
      },
      "enrollment_count": 4000,
      "start_date": "2025-03-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06823115"
    },
    {
      "nct_id": "NCT01285713",
      "title": "IV Glucose for Dehydration Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dehydration"
      ],
      "interventions": [
        {
          "name": "5% Dextrose (D5) in Normal Saline (NS)",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline (NS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Months to 12 Years"
      },
      "enrollment_count": 83,
      "start_date": "2010-09",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01285713"
    },
    {
      "nct_id": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Ponatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2019-05-08",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 275,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 168 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739814"
    },
    {
      "nct_id": "NCT03243630",
      "title": "Effects of Flavors on Nicotine Reinforcement in Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Nicotine Dependence"
      ],
      "interventions": [
        {
          "name": "IV nicotine",
          "type": "DRUG"
        },
        {
          "name": "Menthol flavor",
          "type": "DRUG"
        },
        {
          "name": "green apple",
          "type": "DRUG"
        },
        {
          "name": "green apple and menthol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-04-23",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-03",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03243630"
    },
    {
      "nct_id": "NCT01176565",
      "title": "Antihypertensive Treatment of Acute Cerebral Hemorrhage-II",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Intravenous nicardipine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2011-05-15",
      "completion_date": "2016-03-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-25",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 116,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01176565"
    },
    {
      "nct_id": "NCT04618263",
      "title": "Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Excessive Sleepiness"
      ],
      "interventions": [
        {
          "name": "GATE-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndeio Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-10-26",
      "completion_date": "2021-08-13",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Eatontown, New Jersey",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04618263"
    },
    {
      "nct_id": "NCT05453500",
      "title": "Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tafasitamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2023-03-27",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05453500"
    },
    {
      "nct_id": "NCT07079761",
      "title": "Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",
          "type": "DRUG"
        },
        {
          "name": "Matching IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-08-04",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079761"
    },
    {
      "nct_id": "NCT01685411",
      "title": "Busulfan and Cyclophosphamide Followed By ALLO BMT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Keppra",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic hematopoietic stem cell transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "antithymocyte globulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "44 Years",
        "sex": "ALL",
        "summary": "Up to 44 Years"
      },
      "enrollment_count": 5,
      "start_date": "2013-01",
      "completion_date": "2020-02-10",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685411"
    },
    {
      "nct_id": "NCT02930044",
      "title": "Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Ketoacidosis"
      ],
      "interventions": [
        {
          "name": "Early administration of subcutaneous insulin glargine dose",
          "type": "OTHER"
        },
        {
          "name": "IV insulin infusion",
          "type": "OTHER"
        },
        {
          "name": "IV fluid repletion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-10",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-09-03T06:32:50.747Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930044"
    }
  ]
}